The Alliance for Regenerative Medicine Names 32 Member

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
The Alliance for Regenerative Medicine Names 32 Member Representatives as New Board of Directors

WASHINGTON, DC--(Marketwired - Oct 7, 2015) - The Alliance for Regenerative Medicine (ARM), the international organization representing the gene therapy, cell therapy and tissue engineering sector, announced it has named its new board of directors, effective immediately.

The board's primary responsibilities are to set the overall vision and direction for the organization, in addition to approving the annual budget and voting on any necessary by-law amendments.

"Throughout this process, we've ensured special considerations were made to reflect the diverse focus areas across our membership," said Morrie Ruffin, managing director of ARM. "We welcome this new board and look forward to leveraging their expertise to propel our growing organization forward and continue to promote the sector."

The new board of directors includes ARM's current officers: Edward Lanphier, Chairman; Bob Preti, Vice Chairman; Phil Vanek, Secretary; Claudia Zylberberg, Treasurer.

The board will meet a minimum of three times annually, with at least two of those meetings to be held in-person. There is no set term limit for ARM's board members, however, ARM expects that approximately one-quarter of the board will shift, either during the annual re-election process or owing to voluntary rotation of longest-serving members.

The new board members are as follows:

  • Zami Aberman, CEO, Pluristem Therapeutics
  • Martin Andrews, SVP, Rare Disease Head Unit, GSK
  • Rahul Aras, President and CEO, Juventas
  • Usman Azam, Global Head Cell & Gene Therapies Unit, Novartis
  • Doug Doerfler, President & CEO, MaxCyte
  • Eduardo Bravo, Managing Director and CEO, TiGenix
  • Flagg Flanagan, CEO, DiscGenics
  • Christian Homsy, CEO, Celyad
  • Perry Karsen, CEO, Celgene Cellular Therapeutics
  • Doug Kerr, Senior Director, Neurology Research & Development, Biogen
  • Dena Ladd, Executive Director, Missouri Cures
  • Edward Lanphier, President & CEO, Sangamo BioSciences
  • Michael May, President & CEO, Centre for Commercialization of Regenerative Medicine (CCRM)
  • Randy Mills, President & CEO, California Institute for Regenerative Medicine (CIRM)
  • Matt Patterson, President & CEO, Audentes Therapeutics
  • Steve Paul, President & CEO, Voyager Therapeutics
  • Bob Preti, President & Chief Scientific Officer, PCT, a Caladrius Company
  • Isabelle Riviere, Director, Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  • Martha Rooke, Director, Stem Cell Bioprocessing Group, EMD Millipore Corporation
  • Jay Siegel, Chief Biotechnology Officer and Head, Scientific Strategy, Johnson & Johnson
  • Matthieu Simon, Executive Vice President, Chief Operating Officer, Cellectis
  • Donna Skerrett, Chief Medical Officer, Mesoblast Limited
  • David Smith, Head, Cell Therapy Manufacturing, Lonza
  • Devyn Smith, Head of Strategy for Pharmatherapeutics, Worldwide, Pfizer
  • Doris Taylor, Director, Regenerative Medicine Research, Texas Heart Institute
  • Keith Thompson, CEO, UK Cell Therapy Catapult
  • Gil Van Bokkelen, Chairman and CEO, Athersys
  • Phil Vanek, General Manager, Cell BioProcessing, GE Healthcare
  • Alexander Vos, CEO, PharmaCell
  • Jeff Walsh, COO, bluebird bio
  • Susan Washer, CEO, AGCT
  • Claudia Zylberberg, Founder and CEO, Akron Biotechnology, LLC

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 225 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org .

Michelle Linn (774) 696-3803 linnmich@comcast.net

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
icles